MIM
CHRS icon

Monashee Investment Management’s Coherus Oncology CHRS Stock Holding History

Monashee Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Hold
0
– – – 72
2015
Q2 		– Sell
-100,000
Closed -$3.06M – 77
2015
Q1 		$3.06M Buy
+100,000
New +$2.58M 1.9% 17

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Monashee Investment Management's CHRS Position: Q1 2017 in Review

Monashee Investment Management held its Coherus Oncology (CHRS) position steady in Q1 2017 at 0 shares worth $405K. The position accounts for 0.16% of the portfolio, ranked #72.

Monashee Investment Management first reported a position in CHRS in Q1 2015 and has held it in 1 quarter since. The position peaked at $3.06M in Q1 2015. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

  • Monashee Investment Management held 0 shares of Coherus Oncology worth $405K as of Q1 2017.
  • Monashee Investment Management left its Coherus Oncology share count unchanged in Q1 2017.
  • Coherus Oncology made up 0.16% of Monashee Investment Management's portfolio in Q1 2017, its #72 holding.
  • Monashee Investment Management first reported a position in Coherus Oncology in Q1 2015 and has held it in 1 quarter since.
  • Monashee Investment Management's Coherus Oncology position peaked at $3.06M in Q1 2015.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Monashee Investment Management's 13F filing for Q1 2017, filed 12 May 2017.